Directorate change - Chief Scientific Officer appointment to drive new product development roadmap

Published on 05/11/2020
Directorate change - Chief Scientific Officer appointment to drive new product development roadmap


Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

Directorate change

Chief Scientific Officer appointment to drive new product development roadmap

Manchester, UK – 5 November 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the appointment of Dr. Joanne Mason as Chief Scientific Officer as a director of the Company with immediate effect.

Dr Mason has been director of Research & Development (non-board position) at Yourgene since joining the Company in December 2019, leading the development of next generation molecular diagnostics, particularly in the area of reproductive health.

Dr Mason has been a champion of modernising diagnostics with the use of genomic technologies, having previously held positions as Vice President Biodiscovery with Cambridge Epigenetix, where she led the development of clinical epigenomic technologies and Director of Sequencing and Sample Acquisition for Genomics England, where she managed the delivery of samples and whole genome sequencing for the 100,000 Genomes Project.

She has previously acted as an advisor on the Department of Health (DOH) Rare Disease Policy Board and Forum the Medicines and Healthcare products Regulatory Agency (MHRA) Genomics for Diagnosis Forum and the UK National External Quality Assessment (NEQAS) - Genomics England Steering Committee, Genomics England Sequencing Advisory Board and Bioindustry Association (BIA) Genomics Advisory Committee.

Dr Mason also worked for Oxford University Hospitals NHS Foundation Trust where she set up and managed a NGS Core facility leading translational research, offering disease-specific diagnostic panels and introducing whole genome sequencing into the diagnostic setting. Prior to this role, Dr Mason managed an NGS Core facility in Malaysia and led the Comparative Genomics group at Public Health England studying novel and dangerous pathogens. Dr Mason holds a PhD from Cambridge in Molecular and Cellular Biology.

Dr Bill Chang, continues on the Board as a director, in a new role as Chief Entrepreneur focusing on new scientific collaborations and business ventures for the Group, and remains a significant shareholder.

Lyn Rees, CEO of Yourgene, commented: “I am delighted to welcome Dr Mason to the Board of Yourgene Health. Having worked together for the past year, we have witnessed the tremendous job she has done enabling the launch and commercialisation of key products such as the IONA Nx NIPT Workflow and the Clarigene SARS-CoV-2 test. Adding Dr Mason’s extensive experience within molecular diagnostics to the Board will help us deliver our new product development roadmap and further commercial successes.”

Other than as set out below, there are no other matters required to be disclosed pursuant to paragraph (g) of Schedule Two to the AIM Rules for Companies as regards Dr Joanne Mason’s appointment. Dr Joanne Mason (aged 46) holds 20,700 Ordinary Shares with 750,000 Options.

Current directorships


Directorships in the past 5 years


This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Our Valued Sponsors & Partners